Chronic wounds — defined generally as wounds failing to progress through normal healing stages within four to twelve weeks — represent one of clinical practice’s most persistent challenges. Pressure injuries, diabetic foot ulcers, venous leg ulcers, and post-surgical complications collectively affect millions of patients and represent significant clinical burden.
At the centre of many treatment failures lies a factor that remains underappreciated outside specialist wound care: biofilm.
What Is a Wound Biofilm?
A biofilm is a structured community of microorganisms — bacteria, fungi, or both — encased in a self-produced extracellular matrix of polysaccharides, proteins, and nucleic acids. This matrix adheres to wound surfaces and acts as a physical and biochemical shield, protecting the microorganisms within from:
-
Topical and systemic antimicrobials (antibiotics, antiseptics)
-
The host immune response (including neutrophils and macrophages)
-
Mechanical debridement when incomplete
The distinction between planktonic (free-floating) bacteria and biofilm bacteria is clinically critical. Biofilm-embedded bacteria can require concentrations up to 1,000 times higher than those needed to eliminate planktonic bacteria — concentrations not achievable clinically or safely systemically.
The Prevalence Data: How Common Is Wound Biofilm?
60–100%
Of chronic wounds contain biofilm (vs ~6% of acute wounds)
1,000×
Greater antimicrobial resistance vs planktonic bacteria
24–72h
Biofilm regeneration window after mechanical disruption
⚠️ Clinical Alert: Standard Protocols Often Miss Biofilm
Wounds managed with routine dressing changes and systemic antibiotics may fail to progress due to unaddressed biofilm. If a wound is not progressing within expected timelines, biofilm should be assessed as a likely contributing barrier — not just infection status.
Key 2026 Evidence
Journal of Internal Medicine · August 2026
Biofilm confirmed in 60–100% of chronic wounds
This review confirmed the prevalence range and established biofilm formation as a causal factor in wound chronicity — not merely a downstream complication. The shift from acute to chronic wound status is consistently associated with biofilm establishment.
Frontiers · September 11, 2026
Multidisciplinary Approaches to Enhance Healing in Biofilm-Infected Chronic Wounds
This study examined how established biofilm alters the wound environment in multiple compounding ways: it promotes a sustained inflammatory state, impairs granulation tissue formation, and creates conditions that select for increasingly antibiotic-resistant microbial strains.
Why Standard Wound Care Often Falls Short
Many wound care protocols developed before biofilm’s clinical significance was fully understood relied primarily on systemic antibiotic therapy, standard wound dressings, and topical antiseptic application. These approaches, while effective against planktonic bacteria, frequently fail to adequately disrupt established biofilm.
Clinically, this manifests as wounds that remain “stuck” — not deteriorating rapidly but failing to achieve measurable closure progress. Standard clinical signs of infection may be present but can also be absent in biofilm-chronic wounds, making diagnosis a judgment-based clinical skill.
The 2026 Evidence: Multidisciplinary Management Protocol
1
Serial Sharp Debridement
Foundational. Biofilm regenerates within 24–72 hours of disruption — a single debridement is insufficient. Establish a scheduled, repeated debridement protocol rather than treating it as an occasional intervention.
2
Antimicrobial Wound Dressings
Silver, iodine, or PHMB-based dressings used adjunctively post-debridement. Selection guided by wound profile, exudate levels, and planned duration of use. Prolonged use without reassessment carries its own risks.
3
High-Pressure Irrigation and Wound Cleansing
Surfactant-based cleansers and wound irrigation mechanically dislodge biofilm beyond debridement reach. Early research supports surfactant efficacy in disrupting the biofilm extracellular matrix.
4
Antibiotic Stewardship
Systemic antibiotics retained for spreading cellulitis, osteomyelitis, or systemic infection. Microbiological guidance required — avoid prolonged empirical use given the risk of selecting resistant biofilm strains.
5
Advanced Modalities
Negative pressure wound therapy (mechanical bacterial burden reduction), electrical stimulation (biofilm disruption properties in controlled research), and bacteriophage therapy (investigational in specialist settings) show emerging promise.
Clinical Practice Implications
-
Assess for biofilm in any wound failing to progress within expected timelines — do not default to dressing changes alone
-
Establish a scheduled debridement protocol — not occasional, but structured and repeated
-
Choose antimicrobial dressings based on wound profile and biofilm assessment, not formulary habit
-
Integrate multidisciplinary input — vascular surgery, microbiology, infectious disease, nutrition — for complex non-healing wounds
-
Document with photography and measurement at regular intervals to objectively assess response to biofilm-targeted interventions
Alicorn Medical — Advanced Wound Care Solutions
Our wound care portfolio includes evidence-supported antimicrobial dressings, debridement adjuncts, and irrigation systems. Contact our clinical team for product guidance and evidence-based selection support.
Frequently Asked Questions
Q: How do I know if a wound has biofilm?
Biofilm cannot be reliably identified visually or with standard microbiological swabs. Clinical indicators include wounds that fail to progress despite optimised management and persistent low-level exudate without signs of acute infection. Specialist assessment is often required.
Q: Does debridement remove biofilm permanently?
No. Biofilm regenerates rapidly — often within 24–72 hours — after disruption. This is why a single debridement is insufficient; a scheduled, repeated protocol is the appropriate clinical approach.
Q: Are antimicrobial dressings enough to manage wound biofilm?
Antimicrobial dressings are an important adjunct but typically most effective when used in combination with mechanical debridement. No single intervention addresses all aspects of biofilm management.
Q: What role do antibiotics play in biofilm-infected wounds?
Systemic antibiotics have a role when there is spreading infection or systemic involvement, but are often ineffective against mature, established biofilm. Microbiological guidance and antibiotic stewardship principles should govern their use.
Q: What’s new in biofilm wound research in 2026?
Key 2026 publications (Journal of Internal Medicine, August; Frontiers, September) have reinforced prevalence data and advanced understanding of multidisciplinary management, including debridement scheduling, antimicrobial dressing selection, and emerging modalities